PDXHCI002 - Cell Line (ID:51136)
| HMS LINCS ID: | 51136 |
| Name: | PDXHCI002 |
| Alternative Names: | |
| LINCS ID: | |
| Alternative ID: | |
| Parent Cell Line: | |
| Reference Source: | Dan Stover (Harvard Medical School) |
| Organism: | Homo sapiens |
| Organ: | breast |
| Tissue: | |
| Cell Type: | epithelial |
| Details of Cell Type: | |
| Donor Sex: | female |
| Donor Age: | |
| Donor Ethnicity: | |
| Donor Health Status: | |
| Disease: | DOID: 3008, IDC |
| Details of Disease: | poorly differentiated, medullary type, stage 3A |
| Production Details: | |
| Genetic Modification(s): | none |
| Known Mutations: | |
| Citation Information for Mutations: | |
| Verification Reference Profile: | DNA Profile (STR): Amelogenin: X CSF1PO: 10 D13S317: 9,12 D16S539: 12 D5S818: 12 D7S820: 8,11 THO1: 6,8 TPOX: 8,11 vWA: 17,19 |
| Growth Properties: | adherent |
| Recommended Culture Conditions: | Cells are cultured in F-media: 3:1 mix of complete Dulbecco's MEM (containing 10% fetal bovine serum, 1% penicillin/streptomycin) and Ham's F12 suplemented with 0.125 ng/ml epidermal growth factor, 25 ng/ml hydrocortisone, 5 ug/ml insulin, 8.6 ng/ml cholera toxin, and 5 uM Y-27632 (HMSLID 10176). Protocol: Aspirate spent culture medium, wash cells once with PBS, trypsinize cells with 0.25% trypsin, collect trypsinized cells. Centrifuge at 300 x g for 5 min. Resuspend the cell pellet in F-media, and transfer to fresh plates or flasks. A cubcultivation ratio of 1:2 to 1:6 recommended. |
| Relevant Citations: | PMID 22019887 |
| Usage Note: | |
| Comments: | Established by Dan Stover (Joan Brugge Lab, Harvard Medical School) from a PDX tumor (Alana Welm Lab, University of Utah) |
| Date Publicly Available: | 2018-03-27 |
| Most Recent Update: | 2018-03-27 |
Datasets:
| HMS Dataset ID | Dataset Title | HMS Dataset Type |
|---|---|---|
| 20343 | Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values | Microscopy/Imaging |
| 20344 | Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics | Analysis |
| 20348 | Breast Cancer Profiling Project, Gene Expression 1: Baseline mRNA sequencing on 35 breast cell lines | RNA-Seq |
| 20350 | Breast Cancer Deubiquitinating Enzyme (DUB) Inhibitor Profiling: Fixed-cell GR measures of 21 breast cell lines to 32 small molecule perturbagens. Dataset 1 of 2: Normalized growth rate inhibition values. | Microscopy/Imaging |
| 20351 | Breast Cancer Deubiquitinating Enzyme (DUB) Inhibitor Profiling: Fixed-cell GR measures of 21 breast cell lines to 32 small molecule perturbagens. Dataset 2 of 2: Calculated dose response metrics. | Analysis |
| 20352 | Breast Cancer Profiling Project – Proteomics 1: 1 total proteome dataset for a 35-cell line breast cancer panel under basal conditions | Proteomics |
| 20353 | Breast Cancer Profiling Project – Proteomics 2: 1 phosphoproteome dataset (including phosphotyrosine enrichment) for a 35-cell line breast cancer panel under basal conditions | Proteomics |
| 20373 | DGE-seq Gene expression data for 7 breast cancer cell lines treated with abemaciclib, palbociclib, ribociclib at 0.1, 0.3, 1, or 3 μM, or alvocidib at 0.1 or 1 μM for 6 hours | RNA-Seq |
Batch Information:
| HMS LINCS Batch ID | Provider | Provider Catalog ID | Provider Batch ID |
|---|---|---|---|
| 51136-1 | Dan Stover (Harvard Medical School) |